Travere Therapeutics, Inc. (TVTX) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Travere Therapeutics, Inc. (TVTX) Bundle
Gain insights into your Travere Therapeutics, Inc. (TVTX) valuation analysis using our sophisticated DCF Calculator! This Excel template comes preloaded with actual (TVTX) data, enabling you to adjust forecasts and assumptions for a precise calculation of Travere Therapeutics' intrinsic value.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 175.3 | 198.3 | 227.5 | 212.0 | 145.2 | 141.4 | 137.7 | 134.1 | 130.6 | 127.2 |
| Revenue Growth, % | 0 | 13.11 | 14.71 | -6.8 | -31.5 | -2.62 | -2.62 | -2.62 | -2.62 | -2.62 |
| EBITDA | -107.2 | -144.0 | -186.7 | -299.4 | -326.2 | -117.6 | -114.5 | -111.5 | -108.6 | -105.8 |
| EBITDA, % | -61.15 | -72.59 | -82.06 | -141.22 | -224.63 | -83.16 | -83.16 | -83.16 | -83.16 | -83.16 |
| Depreciation | 20.4 | 25.8 | 26.6 | 20.7 | 38.5 | 20.5 | 20.0 | 19.5 | 19.0 | 18.5 |
| Depreciation, % | 11.64 | 13 | 11.7 | 9.77 | 26.53 | 14.53 | 14.53 | 14.53 | 14.53 | 14.53 |
| EBIT | -127.6 | -169.7 | -213.3 | -320.1 | -364.8 | -127.9 | -124.5 | -121.3 | -118.1 | -115.0 |
| EBIT, % | -72.79 | -85.59 | -93.76 | -151 | -251.16 | -90.43 | -90.43 | -90.43 | -90.43 | -90.43 |
| Total Cash | 398.5 | 361.6 | 552.9 | 450.2 | 566.9 | 141.4 | 137.7 | 134.1 | 130.6 | 127.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 18.0 | 33.1 | 15.9 | 16.6 | 21.2 | 16.0 | 15.5 | 15.1 | 14.7 | 14.3 |
| Account Receivables, % | 10.29 | 16.67 | 7 | 7.85 | 14.58 | 11.28 | 11.28 | 11.28 | 11.28 | 11.28 |
| Inventories | 6.1 | 7.6 | 7.3 | 6.9 | 9.4 | 5.7 | 5.6 | 5.4 | 5.3 | 5.2 |
| Inventories, % | 3.47 | 3.84 | 3.21 | 3.26 | 6.48 | 4.05 | 4.05 | 4.05 | 4.05 | 4.05 |
| Accounts Payable | 26.6 | 12.1 | 15.1 | 17.3 | 41.7 | 18.3 | 17.8 | 17.4 | 16.9 | 16.5 |
| Accounts Payable, % | 15.18 | 6.12 | 6.66 | 8.15 | 28.69 | 12.96 | 12.96 | 12.96 | 12.96 | 12.96 |
| Capital Expenditure | -15.6 | -119.8 | -24.2 | -28.6 | -.7 | -26.5 | -25.9 | -25.2 | -24.5 | -23.9 |
| Capital Expenditure, % | -8.88 | -60.43 | -10.62 | -13.47 | -0.45993 | -18.77 | -18.77 | -18.77 | -18.77 | -18.77 |
| Tax Rate, % | 70.38 | 70.38 | 70.38 | 70.38 | 70.38 | 70.38 | 70.38 | 70.38 | 70.38 | 70.38 |
| EBITAT | -127.6 | -152.3 | -213.8 | -320.5 | -108.0 | -107.3 | -104.5 | -101.7 | -99.0 | -96.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -120.3 | -277.4 | -190.9 | -326.5 | -52.8 | -127.7 | -110.2 | -107.3 | -104.5 | -101.8 |
| WACC, % | 6.96 | 6.85 | 6.96 | 6.96 | 6.21 | 6.79 | 6.79 | 6.79 | 6.79 | 6.79 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -458.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -104 | |||||||||
| Terminal Value | -2,167 | |||||||||
| Present Terminal Value | -1,560 | |||||||||
| Enterprise Value | -2,018 | |||||||||
| Net Debt | 347 | |||||||||
| Equity Value | -2,365 | |||||||||
| Diluted Shares Outstanding, MM | 74 | |||||||||
| Equity Value Per Share | -31.85 |
What You Will Get
- Accurate TVTX Financial Data: Pre-filled with Travere Therapeutics’ historical and projected data for detailed analysis.
- Fully Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Watch Travere Therapeutics’ intrinsic value update in real-time as you make changes.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF results.
- User-Friendly Interface: Intuitive layout and straightforward instructions suitable for all skill levels.
Key Features
- Comprehensive TVTX Data: Pre-loaded with Travere Therapeutics' historical performance metrics and future growth estimates.
- Customizable Assumptions: Modify key inputs such as revenue forecasts, profit margins, discount rates, tax implications, and capital investments.
- Interactive Valuation Framework: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined parameters.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different potential valuation results.
- Intuitive Interface: Designed for ease of use, catering to both seasoned professionals and newcomers.
How It Works
- 1. Access the Template: Download and open the Excel file containing Travere Therapeutics, Inc.'s (TVTX) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically calculates intrinsic value and NPV based on your inputs.
- 4. Explore Different Scenarios: Evaluate various forecasts to assess different valuation possibilities.
- 5. Present with Assurance: Share professional valuation findings to bolster your strategic decisions.
Why Choose This Calculator for Travere Therapeutics, Inc. (TVTX)?
- Designed for Industry Experts: A sophisticated tool utilized by investors, analysts, and healthcare professionals.
- Comprehensive Data: Travere Therapeutics’ historical and projected financials included for precision.
- Flexible Scenario Analysis: Effortlessly model various forecasts and assumptions.
- Detailed Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly Interface: Step-by-step guidance ensures a smooth user experience.
Who Should Use This Product?
- Investors: Accurately estimate Travere Therapeutics’ fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Travere Therapeutics (TVTX).
- Consultants: Efficiently customize the template for valuation reports tailored to Travere Therapeutics (TVTX) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled DCF Model: Travere Therapeutics, Inc.’s (TVTX) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Travere Therapeutics, Inc.’s (TVTX) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.